These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30406175)

  • 1. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.
    Willemse EAJ; van Maurik IS; Tijms BM; Bouwman FH; Franke A; Hubeek I; Boelaarts L; Claus JJ; Korf ESC; van Marum RJ; Roks G; Schoonenboom N; Verwey N; Zwan MD; Wahl S; van der Flier WM; Teunissen CE
    Alzheimers Dement (Amst); 2018; 10():563-572. PubMed ID: 30406175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.
    Dakterzada F; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Piñol-Ripoll G
    Front Aging Neurosci; 2021; 13():604119. PubMed ID: 33746733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.
    Shaw LM; Hansson O; Manuilova E; Masters CL; Doecke JD; Li QX; Rutz S; Widmann M; Leinenbach A; Blennow K
    Clin Biochem; 2019 Oct; 72():7-14. PubMed ID: 31129181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.
    Willemse EAJ; Tijms BM; van Berckel BNM; Le Bastard N; van der Flier WM; Scheltens P; Teunissen CE
    Alzheimers Dement (Amst); 2021; 13(1):e12182. PubMed ID: 33969174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.
    Campbell MR; Ashrafzadeh-Kian S; Petersen RC; Mielke MM; Syrjanen JA; van Harten AC; Lowe VJ; Jack CR; Bornhorst JA; Algeciras-Schimnich A
    Alzheimers Dement (Amst); 2021; 13(1):e12190. PubMed ID: 34027020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
    Schindler SE; Gray JD; Gordon BA; Xiong C; Batrla-Utermann R; Quan M; Wahl S; Benzinger TLS; Holtzman DM; Morris JC; Fagan AM
    Alzheimers Dement; 2018 Nov; 14(11):1460-1469. PubMed ID: 29501462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivation of cutoffs for the Elecsys
    Shaw LM; Waligorska T; Fields L; Korecka M; Figurski M; Trojanowski JQ; Eichenlaub U; Wahl S; Quan M; Pontecorvo MJ; Lachno DR; Talbot JA; Andersen SW; Siemers ER; Dean RA
    Alzheimers Dement (Amst); 2018; 10():698-705. PubMed ID: 30426066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
    Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
    J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elecsys
    Lifke V; Kollmorgen G; Manuilova E; Oelschlaegel T; Hillringhaus L; Widmann M; von Arnim CAF; Otto M; Christenson RH; Powers JL; Shaw LM; Hansson O; Doecke JD; Li QX; Teunissen C; Tumani H; Blennow K
    Clin Biochem; 2019 Oct; 72():30-38. PubMed ID: 31129184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
    Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
    Alzheimers Dement (Amst); 2020; 12(1):e12097. PubMed ID: 32999915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
    Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
    Alzheimers Dement (Amst); 2021; 13(1):e12131. PubMed ID: 33598527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Irwin DJ; Fedler J; Coffey CS; Caspell-Garcia C; Kang JH; Simuni T; Foroud T; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Weintraub D; Mollenhauer B; Galasko DR; Siderowf A; Marek K; Trojanowski JQ; Shaw LM;
    Ann Neurol; 2020 Sep; 88(3):574-587. PubMed ID: 32542885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.
    Doecke JD; Ward L; Burnham SC; Villemagne VL; Li QX; Collins S; Fowler CJ; Manuilova E; Widmann M; Rainey-Smith SR; Martins RN; Masters CL;
    Alzheimers Res Ther; 2020 Mar; 12(1):36. PubMed ID: 32234072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
    Hansson O; Seibyl J; Stomrud E; Zetterberg H; Trojanowski JQ; Bittner T; Lifke V; Corradini V; Eichenlaub U; Batrla R; Buck K; Zink K; Rabe C; Blennow K; Shaw LM; ;
    Alzheimers Dement; 2018 Nov; 14(11):1470-1481. PubMed ID: 29499171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.